Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma (Q43011641)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2010

Language	Label	Description	Also known as
English	Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma	scientific article published in June 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nai-Kong V Cheung

5

object named as

Nai-Kong V Cheung

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Brian H Kushner

1

object named as

Brian H Kushner

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

object named as

Kim Kramer

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Li-Xuan Qin

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3054-3060

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroblastoma in adolescents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroblastoma in adults: Incidence and survival analysis based on SEER data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular resistance to camptothecins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25232

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25232

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43011641&oldid=2187031593"